SABCS 2025

SABCS 2025: Study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring treatment response in patients with bone metastases

SABCS 2025: Preoperative radiation may improve antitumour immune response in most common form of breast cancer

SABCS 2025: Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer

SABCS 2025: Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer

SABCS 2025: Adding tucatinib to first-line maintenance therapy delayed disease progression in HER2-positive metastatic breast cancer in HER2CLIMB-05 trial

SABCS 2025: Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for certain endocrine therapy-refractory advanced breast cancers

SABCS 2025: A multimodal AI model may improve recurrence risk stratification in early breast cancer

SABCS 2025: Latest developments in multigene testing in early breast cancer

Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer

Oncofertility counseling and fertility preservation in premenopausal women with early breast cancer

Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up

Sacituzumab govitecan improves quality of life in untreated advanced TNBC

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years